Imexpharm Corporation
Imexpharm Corporation, a leading pharmaceutical company based in Vietnam, has been a key player in the industry since its establishment in 2003. With its headquarters in Ho Chi Minh City, the company operates extensively across Southeast Asia, focusing on the development, manufacturing, and distribution of high-quality generic medicines and healthcare products. Imexpharm is renowned for its diverse portfolio, which includes a wide range of pharmaceuticals, from antibiotics to cardiovascular medications. The company prides itself on its commitment to quality and innovation, utilising advanced technology and stringent quality control measures to ensure the efficacy and safety of its products. Recognised for its significant contributions to the healthcare sector, Imexpharm has achieved notable milestones, including various certifications and partnerships that enhance its market position. With a strong emphasis on research and development, Imexpharm continues to expand its reach and impact in the pharmaceutical landscape.
DitchCarbon Score
How does Imexpharm Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Imexpharm Corporation's score of 22 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Imexpharm Corporation's reported carbon emissions
Imexpharm Corporation, headquartered in Vietnam, currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that Imexpharm may still be in the early stages of formalising its climate commitments or reporting on its carbon footprint. In the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are often encouraged to establish clear targets for reducing greenhouse gas emissions across all scopes (Scope 1, 2, and 3). As the industry evolves, it will be crucial for Imexpharm to develop and communicate its climate strategies to align with global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Imexpharm Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
